---
title: "SABS.US (SABS.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SABS.US/news.md"
symbol: "SABS.US"
name: "SABS.US"
parent: "https://longbridge.com/en/quote/SABS.US.md"
datetime: "2026-03-08T06:31:08.458Z"
locales:
  - [en](https://longbridge.com/en/quote/SABS.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SABS.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SABS.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/SABS.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/SABS.US/news.md)


# SABS.US (SABS.US) — Related News

### [SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf](https://longbridge.com/en/news/277368379.md)
*2026-03-01T19:43:57.000Z*
> SAB Biotherapeutics presented its strategy for type 1 diabetes (T1D) at Oppenheimer’s 36th Annual Healthcare Life Scienc

### [Zhongyu Trogarzo is not affected by the U.S. Section 122 tariff measures and maintains a zero tariff](https://longbridge.com/en/news/276974571.md)
*2026-02-26T02:51:39.000Z*
> Zhongyu (4147-TW) stated that Trogarzo's manufacturer, Samsung Biologics, confirmed that the drugs exported from South K

### [08:59 ETJoe Kiani Appointed Chairman of SMSbiotech to Accelerate Growth and Advance Regenerative Cell Therapy Innovation](https://longbridge.com/en/news/276609600.md)
*2026-02-23T14:00:36.000Z*
> SMSbiotech has appointed Joe Kiani as Chairman of the Board of Directors to enhance its growth in regenerative cell ther

### [SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Analysts](https://longbridge.com/en/news/276099205.md)
*2026-02-17T06:55:12.000Z*
> SAB Biotherapeutics, Inc. (NASDAQ:SABS) has received a consensus rating of "Moderate Buy" from six research firms. One a

### [SAB Biotherapeutics Spotlights SAB-142 Phase 2b Plan in Type 1 Diabetes at Guggenheim Summit 2026](https://longbridge.com/en/news/275996619.md)
*2026-02-15T06:05:34.000Z*
> SAB Biotherapeutics (NASDAQ:SABS) presented its Phase 2b plan for SAB-142 in type 1 diabetes at the Guggenheim Emerging 

### [08:00 ETSamsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system](https://longbridge.com/en/news/275128718.md)
*2026-02-06T13:00:37.000Z*
> Samsung Biologics has announced the independent validation of its Product Carbon Footprint (PCF) system by Det Norske Ve

### [Kymera Therapeutics to Participate in Guggenheim Biotech Summit and Oppenheimer Healthcare Conference](https://longbridge.com/en/news/274807457.md)
*2026-02-04T12:01:06.000Z*
> Kymera Therapeutics Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11 at 9:00

### [CEPI and Samsung Biologics partner to boost global vaccine preparedness](https://longbridge.com/en/news/274795677.md)
*2026-02-04T09:33:18.000Z*
> CEPI and Samsung Biologics have formed a partnership to enhance global vaccine preparedness for pandemics. Samsung Biolo

### [04:09 ET
			
			
				Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026](https://longbridge.com/en/news/274627440.md)
*2026-02-03T09:10:36.000Z*
> Swedish Orphan Biovitrum AB (Sobi) announced its participation in the 19th Annual Congress of the European Association f

### [SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of "Moderate Buy" by Brokerages](https://longbridge.com/en/news/273485779.md)
*2026-01-23T08:26:33.000Z*
> SAB Biotherapeutics, Inc. (NASDAQ:SABS) has received a consensus rating of "Moderate Buy" from six research firms. One a